牛牛AI助理已提取核心訊息
iBio Inc, a biotechnology company based in Bryan, Texas, has announced a significant change in its financial oversight structure. On February 15, 2024, the company's Audit Committee initiated a competitive process to select a new independent registered public accounting firm for the fiscal year ending June 30, 2024. This process led to the engagement of Grassi & Co., CPAs, P.C. as the new auditor, with the formal engagement beginning on February 20, 2024. The change comes after the resignation of the previous auditor, CohnReznick LLP, which occurred on the same day as the initiation of the search for their replacement. CohnReznick's resignation was not due to any disagreements on accounting principles or practices, financial statement disclosure, or auditing scope or procedure. However, it is...Show More
iBio Inc, a biotechnology company based in Bryan, Texas, has announced a significant change in its financial oversight structure. On February 15, 2024, the company's Audit Committee initiated a competitive process to select a new independent registered public accounting firm for the fiscal year ending June 30, 2024. This process led to the engagement of Grassi & Co., CPAs, P.C. as the new auditor, with the formal engagement beginning on February 20, 2024. The change comes after the resignation of the previous auditor, CohnReznick LLP, which occurred on the same day as the initiation of the search for their replacement. CohnReznick's resignation was not due to any disagreements on accounting principles or practices, financial statement disclosure, or auditing scope or procedure. However, it is noted that the company's financial statements for the fiscal year ended June 30, 2023, included an explanatory paragraph regarding the company's ability to continue as a going concern. Additionally, a material weakness in controls related to accounting for stock-based compensation expense was identified and subsequently remediated in the same fiscal year. iBio Inc has filed the required letter from CohnReznick with the SEC, confirming their agreement with the statements made by the company regarding their resignation.
總部位於德克薩斯州布萊恩的生物技術公司iBio Inc宣佈其財務監督結構發生重大變化。2024年2月15日，該公司的審計委員會啓動了競爭程序，爲截至2024年6月30日的財政年度選擇一家新的獨立註冊會計師事務所。這一過程促使Grassi & Co.、CPA、P.C. 被聘爲新的核數師，正式聘用將於2024年2月20日開始。這一變化是在前任核數師CohnrezNick LLP辭職之後發生的，辭職發生在開始尋找接班人的同一天。CohnrezNick的辭職不是因爲在會計原則或慣例、財務報表披露或審計範圍或程序上存在任何分歧。但是，值得注意的是，該公司截至2023年6月30日的財年財務報表中有一段關於公司繼續經營能力的解釋性段落。此外，在與股票薪酬支出會計相關的控制措施中發現了一個重大缺陷，隨後在同一財年進行了補救。iBio Inc已向美國證券交易委員會提交了CohnrezNick的必要信函，確認他們同意該公司就其辭職發表的聲明。
總部位於德克薩斯州布萊恩的生物技術公司iBio Inc宣佈其財務監督結構發生重大變化。2024年2月15日，該公司的審計委員會啓動了競爭程序，爲截至2024年6月30日的財政年度選擇一家新的獨立註冊會計師事務所。這一過程促使Grassi & Co.、CPA、P.C. 被聘爲新的核數師，正式聘用將於2024年2月20日開始。這一變化是在前任核數師CohnrezNick LLP辭職之後發生的，辭職發生在開始尋找接班人的同一天。CohnrezNick的辭職不是因爲在會計原則或慣例、財務報表披露或審計範圍或程序上存在任何分歧。但是，值得注意的是，該公司截至2023年6月30日的財年財務報表中有一段關於公司繼續經營能力的解釋性段落。此外，在與股票薪酬支出會計相關的控制措施中發現了一個重大缺陷，隨後在同一財年進行了補救。iBio Inc已向美國證券交易委員會提交了CohnrezNick的必要信函，確認他們同意該公司就其辭職發表的聲明。
有用
沒用
